exceptional service across specialties

The journey for patients with complex, hard-to-diagnose diseases can be long and challenging. Many spend years moving from one specialist to another before receiving a diagnosis, and managing treatment and related difficulties can be a daily struggle.

As a specialty pharmacy focused on supporting patients with these complex conditions, we are committed to guiding you through every stage of theat journey, both clinically and administratively to help you achieve the best possible outcomes. Out Therapy Care Teams are extensively trained in each condition we support, allowing us to tailor our approach to meet the unique needs of every patient. Learn more about the conditions and therapies we support below.

Asthma & Allergy

Asthma is a long term condition causing inflammation to the airways and making it difficult to breathe.

Bleeding Disorders

There are several bleeding disorders such as Hemophilia, Von Willebrand disease, and several clotting factors deficiencies.

Hepatitis B

Chronic Hepatitis B is a virus transmitted by bodily fluids that can lead to serious liver damage.

Hepatitis C

Hepatitis C is an infection caused by a bloodborne virus affecting the liver.

HIV

HIV is a serious viral infection that attacks the body’s immune system and if left untreated can seriously impair the body’s ability to fight off infections.

Inflammatory Bowel Disease

IBD is inflammation of the GI tract manifesting in either Crohn’s disease or Ulcerative colitis.

Multiple Sclerosis

MS is a very complex disease affecting the central nervous system.

Oncology

Oncology involves several different types of cancer and can affect multiple areas of the body.

Pulmonary Hypertension

PH is a rare condition in which high blood pressure occurs specifically in the lungs.

Rheumatology

Many rheumatologic diseases are autimmune conditions often times affecting the joints.

Sickle Cell Disease

Sickle cell disease is caused by a hereditary condition affecting the red blood cells.

Transplant

Transplant refers to the life-saving organ transplantation of a healthy organ to another individual.

Search by Drug

Search by Condition or Specialty

  • Abrilada

    • Drug: Abrilada (adalimumab-afzb)
    • Manufacturer: Pfizer

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older
        • treatment of moderately to severely active ulcerative colitis in adult patients
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate
        • treatment of moderate to severe hidradenitis suppurativa in adult patients
        • treatment of non-infectious intermediate, posterior, and panuveitis in adult patients
    • Disease: ankylosing spondylitis, Crohn’s disease, hidradenitis suppurativa, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, uveitis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.pfizerencompass.com

    • Phone Number: 1-844-722-6672
    • Fax Number: 1-833-626-5384
    • Product Website: abrilada.com

  • Adempas

    • Drug: Adempas (riociguat)
    • Manufacturer: Bayer
    • Route of Administration: Oral
    • Site of Care: Outpatient

    • Approved Indication:

      • persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and functional class
      • pulmonary arterial hypertension (WHO group 1) to improve exercise capacity, improve functional class, and delay clinical worsening
    • Disease: chronic thromboembolic pulmonary hypertension, pulmonary arterial hypertension
    • Therapeutic Area: Pulmonary
    • Enrollment Form Link: www.adempashcp.com/forms
    • Phone Number: 1-855-423-3672
    • Fax Number: 1-855-662-5200

    • Product Website:

  • ambrisentan

    • Drug: ambrisentan
    • Manufacturer: Gilead
    • Route of Administration: Oral
    • Site of Care: Outpatient

    • Approved Indication: to improve exercise ability and delay clinical worsening in combination with tadalafil to reduce the risks of disease progression and hospitalization for worsening WHO group 1 pulmonary arterial hypertension

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: N/A

    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: letairis.com

  • Amjevita

    • Drug: Amjevita (adalimumab-atto)
    • Manufacturer: Amgen

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

        • reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis
        • reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
        • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis
        • reducing signs and symptoms in adult patients with active ankylosing spondylitis
        • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderate to severely active Crohn’s Disease who have had an inadequate response to conventional therapy. Reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab
        • inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine
        • treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate

    • Disease: ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: www.amgensupportplus.com/patient/amjevita

    • Phone Number: 1-888-826-5384

    • Fax Number: 1-833-626-5384

    • Product Website: amjevita.com

  • Avsola

    • Drug: Avsola (infliximab-axxq)

    • Manufacturer: Amgen

    • Route of Administration: Intravenous
    • Site of Care: Outpatient

    • Approved Indication:

        • reducing signs and symptoms and inducing and maintaining clinical remission in adults or pediatric patients 6 years of age and older with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy
        • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease
        • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy
        • [in combination with methotrexate] reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease
        • reducing signa and symptoms in adult patients with active ankylosing spondylitis
        • reducing signa and symptoms of active psoriatic arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients
        • treatment of adult patients with chronic severe plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate
    • Disease: ankylosing spondylitis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis

    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology

    • Enrollment Form Link: www.avsola.com/HCP/support
    • Phone Number: 866-264-2778
    • Fax Number: N/A

    • Product Website: avsola.com

  • bosentan

    • Drug: bosentan
    • Manufacturer: misc
    • Route of Administration: Oral
    • Site of Care: Outpatient

    • Approved Indication:

      • treatment of pulmonary arterial hypertension (WHO group 1) in adults to improve exercise ability and to decrease clinical worsening
      • treatment of pulmonary arterial hypertension (WHO group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance which is expected to result in an improvement in exercise ability

    • Disease: pulmonary arterial hypertension

    • Therapeutic Area: Pulmonary

    • Enrollment Form Link: www.bosentanREMSprogram.com
    • Phone Number: 1-866-359-2612
    • Fax Number: 1-800-730-8231
    • Product Website: www.tracleer.com

  • budesonide

    • Drug: budesonide
    • Manufacturer: misc
    • Route of Administration: Oral
    • Site of Care: Outpatient

    • Approved Indication: Crohn’s disease, ulcerative colitis

    • Disease: Crohn’s disease, lymphocytic colitis, microscopic colitis, ulcerative colitis
    • Therapeutic Area: Gastroenterology
    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A

    • Product Website: N/A

  • calcitriol

    • Drug: calcitriol
    • Manufacturer: misc
    • Route of Administration: Oral
    • Site of Care: Outpatient

    • Approved Indication:

      • managing secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15-55 mL/min)
      • managing hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis
      • managing hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism
    • Disease: hypocalcemia, secondary hyperparathyroidism
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology, Immunology
    • Enrollment Form Link: N/A
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: N/A

  • CellCept

    • Drug: CellCept (mycophenolate mofetil)
    • Manufacturer: Genentech

    • Route of Administration: Oral

    • Site of Care: Outpatient
    • Approved Indication: prophylaxis of organ rejection in adult and pediatric recipients 3 months of age and older of allogenic kidney, heart, or liver transplants, in combination with other immunosuppressants

    • Disease: solid organ transplant

    • Therapeutic Area: Solid Organ Transplant
    • Enrollment Form Link: www.mycophenolaterems.com
    • Phone Number: N/A
    • Fax Number: N/A
    • Product Website: cellcept.com

  • Cimzia

    • Drug: Cimzia (certolizumab pegol)
    • Manufacturer: UCB, Inc.

    • Route of Administration: Subcutaneous

    • Site of Care: Outpatient
    • Approved Indication:

      • reducing signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy
      • treatment of adults with moderately to severely active rheumatoid arthritis/strong>

      • treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
      • treatment of adult patients with active psoriatic arthritis
      • treatment of adults with active ankylosing spondylitis
      • treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation
      • treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy

    • Disease: ankylosing spondylitis, Crohn’s disease, juvenile idiopathic arthritis, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis
    • Therapeutic Area: Gastroenterology, Rheumatology, Dermatology
    • Enrollment Form Link: ucbimmunologysupport.com/cimzia
    • Phone Number: 1-866-424-6942
    • Fax Number: 1-866-949-2469

    • Product Website: cimzia.com